RecruitingPhase 2NCT05999994

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric Research


Sponsor

Eli Lilly and Company

Enrollment

105 participants

Start Date

Jan 22, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.


Eligibility

Min Age: 1 YearMax Age: 39 Years

Inclusion Criteria6

  • Have either measurable or evaluable disease using standard techniques by the Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).
  • The participant has a Lansky (\<16 years of age) or Karnofsky (≥16 years of age) performance score of at least 50.
  • Participants must have discontinued all previous treatments for cancer or investigational agents greater than or equal to (≥)7 days after the last dose and must have recovered from clinically significant side effects.
  • The participant has adequate hematologic and organ function.
  • Female participants of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to first dose.
  • Both female and male participants of childbearing potential must agree to use highly effective contraceptive precautions during the trial and for at least 3 months following the last dose of study drug.

Exclusion Criteria5

  • Participants with severe and/or uncontrolled concurrent medical disease or psychiatric illness/social situation that, in the opinion of the investigator, could cause unacceptable safety risks or compromise compliance with the protocol.
  • Participants who have active infections requiring therapy.
  • Participants who have had allogeneic bone marrow or solid organ transplant.
  • Participants who have had, or are planning to have, certain invasive procedures.
  • Female participants who are pregnant or breastfeeding.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRamucirumab

Administered IV

DRUGCyclophosphamide

Administered orally

DRUGVinorelbine

Administered IV

DRUGGemcitabine

Administered IV

DRUGDocetaxel

Administered IV

DRUGAbemaciclib

Administered orally

DRUGIrinotecan

Administered IV

DRUGTemozolomide

Administered orally


Locations(73)

Childrens Hospital of Alabama

Birmingham, Alabama, United States

Phoenix Children's Hospital

Phoenix, Arizona, United States

Phoenix Children's Hospital

Phoenix, Arizona, United States

Childrens Hospital of Los Angeles

Los Angeles, California, United States

UCLA Medical Center

Los Angeles, California, United States

Children's Hospital of Orange County

Orange, California, United States

Children's Hospital of Colorado

Denver, Colorado, United States

Children's National Medical Center

Washington D.C., District of Columbia, United States

Golisano Children's Hospital of Southwest Florida

Fort Myers, Florida, United States

Mayo Clinic in Florida

Jacksonville, Florida, United States

Children's Healthcare of Atlanta, Inc. at Egleston

Atlanta, Georgia, United States

Ann & Robert H Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

Riley Hospital for Children

Indianapolis, Indiana, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

C.S. Mott Children's Hospital

Ann Arbor, Michigan, United States

University of Minnesota Hospital

Minneapolis, Minnesota, United States

Children's Mercy Hospital

Kansas City, Missouri, United States

Washington University Medical School

St Louis, Missouri, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Nationwide Children's Hosp

Columbus, Ohio, United States

Oregon Health and Science University

Portland, Oregon, United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

UPMC Children's Hospital of Pittsburgh

Pittsburgh, Pennsylvania, United States

Lifespan Cancer Institute

Providence, Rhode Island, United States

University of Texas Southwestern Medical Center at Dallas

Dallas, Texas, United States

Cook Children's Hospital

Fort Worth, Texas, United States

Texas Childrens Hospital

Houston, Texas, United States

University of Texas MD Anderson Cancer Center

Houston, Texas, United States

Seattle Children's Hospital Research Foundation

Seattle, Washington, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Chris O'Brien Lifehouse

Camperdown, Australia

Peter MacCallum Cancer Centre

Melbourne, Australia

Royal Children's Hospital

Melbourne, Australia

The Sydney Children's Hospitals Network

Westmead, Australia

UCL- Saint Luc

Brussels, Belgium

Universitair Ziekenhuis Gent

Ghent, Belgium

Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest

Bordeaux, France

Centre Leon Berard

Lyon, France

Centre Leon Berard

Lyon, France

Institut Curie

Paris, France

Universitaetsklinikum Essen

Essen, Germany

Universitaetsklinikum Freiburg

Freiburg im Breisgau, Germany

Universitaetsklinikum Hamburg-Eppendorf

Hamburg, Germany

IRCCS Istituto Ortopedico Rizzoli

Bologna, Italy

Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia

Candiolo, Italy

Istituto Nazionale dei Tumori

Milan, Italy

Azienda Ospedaliera Di Padova

Padova, Italy

Ospedale Bambino Gesu

Roma, Italy

Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore

Roma, Italy

Istituto Clinico Humanitas

Rozzano, Italy

National Cancer Center Hospital

Chūōku, Japan

Kyushu University Hospital

Fukuoka, Japan

Hyogo Prefectural Kobe Children's Hospital

Kobe, Japan

Leids Universitair Medisch Centrum

Leiden, Netherlands

Prinses Maxima Centrum

Utrecht, Netherlands

Hospital de la Santa Creu i Sant Pau

Barcelona, Spain

Hospital Universitari Vall d'Hebron

Barcelona, Spain

Hospital Universitari Vall d'Hebron

Barcelona, Spain

Hospital Sant Joan de Déu

Esplugues de Llobregat, Spain

Hospital General Universitario Gregorio Marañon

Madrid, Spain

Hospital General Universitario Gregorio Marañon

Madrid, Spain

Hospital Infantil Universitario Niño Jesús

Madrid, Spain

Hospital Universitario La Paz

Madrid, Spain

Hospital Universitario La Paz

Madrid, Spain

Hospital Universitario de Canarias

San Cristóbal de La Laguna, Spain

Hospital Universitario Virgen Del Rocio

Seville, Spain

Hospital Universitario Virgen Del Rocio

Seville, Spain

Hospital Universitari i Politecnic La Fe

Valencia, Spain

University College Hospital - London

London, United Kingdom

Royal Marsden Hospital

London, United Kingdom

Royal Marsden Hospital

London, United Kingdom

Royal Manchester Children's Hospital

Manchester, United Kingdom

The Christie NHS Foundation Trust

Manchester, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05999994


Related Trials